Activation of the HIF pathway in childhood ALL, prognostic implications of VEGF. (Q47967619)

7 February 2018

title

Activation of the HIF pathway in childhood ALL, prognostic implications of VEGF. (English)

1 reference

7 February 2018

author name string

S Wellmann

1

1 reference

7 February 2018

M Guschmann

2

1 reference

7 February 2018

W Griethe

3

1 reference

7 February 2018

C Eckert

4

1 reference

7 February 2018

A von Stackelberg

5

1 reference

7 February 2018

C Lottaz

6

1 reference

7 February 2018

E Moderegger

7

1 reference

7 February 2018

H G Einsiedel

8

1 reference

7 February 2018

K-U Eckardt

9

1 reference

7 February 2018

G Henze

10

1 reference

7 February 2018

K Seeger

11

1 reference

7 February 2018

publication date

1 May 2004

1 reference

7 February 2018

published in

Leukemia

1 reference

7 February 2018

volume

18

1 reference

7 February 2018

issue

5

1 reference

7 February 2018

page(s)

926-933

1 reference

7 February 2018

Angiogenesis in cancer and other diseases

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403332

Blood vessel formation: what is its molecular basis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403332

The role of VEGF in normal and neoplastic hematopoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403332

Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403332

Cellular adaptation to hypoxia: O2-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O2-regulated gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403332

Hypoxia--a key regulatory factor in tumour growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403332

The HIF family member EPAS1/HIF-2α is required for normal hematopoiesis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403332

Modeling pO(2) distributions in the bone marrow hematopoietic compartment. I. Krogh's model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403332

Modeling pO(2) distributions in the bone marrow hematopoietic compartment. II. Modified Kroghian models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403332

Abnormal B lymphocyte development and autoimmunity in hypoxia-inducible factor 1alpha -deficient chimeric mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403332

Expression of hypoxia-inducible factor-1alpha and -2alpha in hypoxic and ischemic rat kidneys

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403332

Control genes and variability: absence of ubiquitous reference transcripts in diverse mammalian expression studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403332

The Expression and Distribution of the Hypoxia-Inducible Factors HIF-1α and HIF-2α in Normal Human Tissues, Cancers, and Tumor-Associated Macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403332

Expression of angiogenic factors and hypoxia inducible factors HIF 1, HIF 2 and CA IX in non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403332

Nuclear expression of hypoxia-inducible factor 1alpha protein is heterogeneous in human malignant cells under normoxic conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403332

BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403332

Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403332

Increased cellular hypoxia and reduced proliferation of both normal and leukaemic cells during progression of acute myeloid leukaemia in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403332

Measuring hypoxia in solid tumours--is there a gold standard?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403332

VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403332

VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403332

Vascular endothelial growth factor (VEGF) and its receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403332

7 January 2021

Increased angiogenesis in bone marrow of children with acute lymphoblastic leukaemia has no prognostic significance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403332

7 January 2021

Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403332

7 January 2021

Comparison between pediatric acute myeloid leukemia (AML) and adult AML in VEGF and KDR (VEGF-R2) protein levels

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403332

7 January 2021

Kinetics of hemopoietic stem cells in a hypoxic culture

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403332

7 January 2021

HIF-1 is essential for multilineage hematopoiesis in the embryo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403332

7 January 2021

Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403332

7 January 2021

Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403332

7 January 2021

Long-term results of large prospective trials in childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403332

7 January 2021

Co-operative study group for childhood acute lymphoblastic leukemia (COALL): long-term follow-up of trials 82, 85, 89 and 92

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403332

7 January 2021

Changing bone marrow micro-environment during development of acute myeloid leukaemia in rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403332

7 January 2021

Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403332

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2403332

1 reference

7 February 2018

1 reference

7 February 2018